Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00216190 · ClinicalTrials.gov registry record · Phase 4
A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation
A Phase 4 study, sponsored by Hospira, now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 420
- Enrollment target
NCT00216190 is a Phase 4 study that has completed, run by Hospira, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 420 participants.
The verdict
NCT00216190, a Phase 4 study, has completed, sponsored by Hospira, now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 420 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects who are initially intubated, mechanically ventilated and require sedation for beyond 24 hours.
Interventions
- DRUG Dexmedetomidine HCL Injection
- DRUG Midazolam Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00216190
The ClinicalTrials.gov registry entry for NCT00216190 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospira, now a wholly owned subsidiary of Pfizer, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexmedetomidine HCL Injection is the first listed.
NCT00216190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00216190 about?
NCT00216190 is a clinical study titled "A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation". The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects who are initially intubated, mechanically ventilated and require sedation for beyond 24 hours.
What is the current status of trial NCT00216190?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 420 participants. The study started on 2005-03. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00216190?
The interventions under investigation include: Dexmedetomidine HCL Injection (DRUG), Midazolam Injection (DRUG).
Who is sponsoring clinical trial NCT00216190?
This trial is sponsored by Hospira, now a wholly owned subsidiary of Pfizer, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.